Skip to Content

Generic Natroba Availability

Last updated on Sep 8, 2021.

Natroba is a brand name of spinosad topical, approved by the FDA in the following formulation(s):

NATROBA (spinosad - suspension;topical)

  • Manufacturer: PARAPRO LLC
    Approval date: January 18, 2011
    Strength(s): 0.9% [RLD]

Has a generic version of Natroba been approved?

No. There is currently no therapeutically equivalent version of Natroba available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natroba. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Formulations for controlling human lice
    Patent 6,063,771
    Issued: May 16, 2000
    Inventor(s): Snyder; Daniel Earl
    Assignee(s): Eli Lilly and Company

    Safer pediculicidal formulations comprising a spinosyn, or a physiologically acceptable derivative or salt thereof, and a physiologically acceptable carrier, and methods of controlling lice infestations in a human with these formulations are provided.

    Patent expiration dates:

    • July 25, 2023
      ✓ 
      Patent use: NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
      ✓ 
      Drug product
  • Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs
    Patent 7,030,095
    Issued: April 18, 2006
    Inventor(s): Janssen; Herwig & Ho; Kie & Nystrand; Glenn & Williams; Dexter & Lamb; C. Scott
    Assignee(s): Johnson & Johnson Consumer Companies, Inc.

    The present invention relates to composition and methods for administering compositions in solutions for killing adult lice and the ova comprising water, PVM/MA Decadiene crosspolymers, propylene glycol, a mixture of cetyl and stearyl alcohols, Ceteareth-20; stearalkonium chloride; benzyl alcohol; hexylene glycol; pentylene glycol, isopropyl alcohol; a mixture of spinosyn A and spinosyn D in a weight ratio of 80:20, BHT; and sodium hydroxide.

    Patent expiration dates:

    • July 2, 2021
      ✓ 
      Patent use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • April 28, 2024 - FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.